clinical trial · NCT07449923
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals, Inc.·phase3·recruiting·n = 240
Diabetic Macular EdemaDMEDiabetic Macular Edema (DME)EYP-1901Aflibercept (2.0 mg)
brief summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
started
Feb 9, 2026
primary completion
Oct 1, 2027
completion
Oct 1, 2028
last updated
Jun 3, 2026
official title
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol